CONTENTS
Assistant Editor
Special Assignments
julia aalbers
Tel: 021 976 4378
Fax: 086 610 3395
e-mail:
Production Editor
SHAUNA GERMISHUIZEN
Tel: 021 785 7178
Fax: 086 628 1197
e-mail:
Editorial Assistant &
Circulation
ELSABÉ BURMEISTER
Tel: 021 976 8129
e-mail:
Production
Co-ordinator
WENDY WEGENER
Tel: (021) 976-4378
e-mail:
GAUTENG CONTRIBUTOR
PETER WAGENAAR
Cell 082 413 9954
e-mail :
The
Cardiovascular Journal of Africa
,
incorporating the
Cardiovascular
Journal of South Africa
, is published six
times a year, the deemed publication
date being the seventh day of the
second designated month,
i.e. 7 February, 7 April, 7 June, 7
August, 7 October and 7 December.
Copyright:
Clinics Cardive Publishing, Pty, Ltd.
Layout:
Martingraphix
Printer:
Durbanville Commercial Printers
All submissions to CVJA are to be
made online via
Electronic submission by means of an
e-mail attachment may be considered
under exceptional circumstances.
Postal address: PO Box 1013,
Durbanville, 7551
Tel/Fax: 021 976 8129
Int.: +27 21 976 8129
e-mail:
Electronic abstracts available on
Pubmed
Audited circulation
Full text articles available on:
or via
co.za; for access codes contact
User ID: cvja8
Password: cvja8
Subscriptions for six issues:
South Africa: R420 (excl VAT)
Other African countries: $60
Overseas: Institutions: R1023 ($146)
Overseas: Individuals R1306 ($186)
The views and opinions expressed
in the articles and reviews published
are those of the authors and do not
necessarily reflect those of the editors
of the Journal or its sponsors. In all
clinical instances, medical practitioners
are referred to the product insert
documentation as approved by the
relevant control authorities.
VOL 22, NO 1. JANUARY / FEBRUARY 2011
37
Letter to the Editor
FO Muller
Review Article
38 Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
RP Morrissey • KJ Philip • ER Schwarz
Opinions in Hypertension Management
45 Improving hypertension control in patients at cardiovascular risk: the case for
telmisartan-based therapy
J Aalbers
Industry News
48 Boehringer Ingelheim and Eli Lilly and Company announce strategic alliance to bring new
diabetes treatments to patients worldwide
Drug Trends
50 South African experts comment on FDA approval of dabigatran in atrial fibrillation
E Klug • A Bryer • J Aalbers
ASCOT analysis with atorvastatin shows limits of CRP as indicator of cardiovascular risk
Chronic heart failure treatment benefits from pro-BNP-directed therapy
J Aalbers
Fenofibrate profiled as the fibrate with additional
new data, supporting its use with statins in the
European Medicines Agency recommendations
Cardio News
56 PACE quilt project
It's the
shell that
makes
safer.
R
Safety-Coated
R
81mg
The ORIGINAL low dose aspirin
for optimum cardio-protection
Hp
Each tablet contains Aspirin 81mg. Reg.No.: 29/2.7/0767
Pharmafrica (Pty) Ltd, 33 Hulbert Road, New Centre, Johannesburg 2001
Under licence from Goldshield Pharmaceuticals Ltd. U.K.
